Want to see OLMA full AI Analyst Report?
Total Valuation
Olema Pharmaceuticals has a market cap or net worth of $994.89M. The enterprise value is $772.97M.
Market Cap$994.89M
Enterprise Value$772.97M
Share Statistics
Olema Pharmaceuticals has 87,347,470 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding87,347,470
Owned by Insiders2.67%
Owned by Institutions61.04%
Financial Efficiency
Olema Pharmaceuticals’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -37.02%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-37.02%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee0.00
Profits Per Employee-1.69M
Employee Count96
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Olema Pharmaceuticals is ―. Olema Pharmaceuticals’s PEG ratio is 0.89.
PE Ratio―
PS Ratio0.00
PB Ratio4.55
Price to Fair Value4.55
Price to FCF-14.83
Price to Operating Cash Flow-7.87
PEG Ratio0.89
Income Statement
In the last 12 months, Olema Pharmaceuticals had revenue of 0.00 and earned -162.45M in profits. Earnings per share was -1.87.
Revenue0.00
Gross Profit0.00
Operating Income-178.70M
Pretax Income-162.45M
Net Income-162.45M
EBITDA-161.96M
Earnings Per Share (EPS)-1.87
Cash Flow
In the last 12 months, operating cash flow was -148.72M and capital expenditures 0.00, giving a free cash flow of -148.72M billion.
Operating Cash Flow-148.72M
Free Cash Flow-148.72M
Free Cash Flow per Share-1.70
Dividends & Yields
Olema Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.00
52-Week Price Change167.37%
50-Day Moving Average12.96
200-Day Moving Average17.14
Relative Strength Index (RSI)50.67
Average Volume (3m)1.47M
Important Dates
Olema Pharmaceuticals upcoming earnings date is Aug 11, 2026, After Close (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Olema Pharmaceuticals as a current ratio of 9.95, with Debt / Equity ratio of 0.20%
Current Ratio9.95
Quick Ratio9.95
Debt to Market Cap<0.01
Net Debt to EBITDA0.29
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Olema Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Olema Pharmaceuticals EV to EBITDA ratio is -13.14, with an EV/FCF ratio of -14.50.
EV to Sales0.00
EV to EBITDA-13.14
EV to Free Cash Flow-14.50
EV to Operating Cash Flow-14.50
Balance Sheet
Olema Pharmaceuticals has $505.35M in cash and marketable securities with $956.00K in debt, giving a net cash position of $504.39M billion.
Cash & Marketable Securities$505.35M
Total Debt$956.00K
Net Cash$504.39M
Net Cash Per Share$5.77
Tangible Book Value Per Share$5.50
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Olema Pharmaceuticals is $38.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$38.14
Price Target Upside126.77% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast-3.83%